Formula 7 - The Solution
Tolnaftate
The Tetra Corporation
Human Otc Drug
NDC 49406-007Formula 7 - The Solution also known as Tolnaftate is a human otc drug labeled by 'The Tetra Corporation'. National Drug Code (NDC) number for Formula 7 - The Solution is 49406-007. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Formula 7 - The Solution drug includes Tolnaftate - 1 g/100g . The currest status of Formula 7 - The Solution drug is Active.
Drug Information:
| Drug NDC: | 49406-007 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Formula 7 - The Solution |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Tolnaftate |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | The Tetra Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Solution |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TOLNAFTATE - 1 g/100g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 13 Jun, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 15 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333C |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | The Tetra Corporation
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 313423
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 06KB629TKV
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 49406-007-15 | 15 g in 1 PACKAGE (49406-007-15) | 13 Jun, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Uses: antifungal
Product Elements:
Formula 7 - the solution tolnaftate water jojoba oil glycerin oleth-10 oleth-5 oleth-3 phosphate peg-20 hydrogenated lanolin butylene glycol urea alkyl (c12-15) benzoate .alpha.-tocopherol acetate tea tree oil ethylhexylglycerin caprylyl glycol phenoxyethanol acetylcysteine aminomethylpropanol sodium chloride tolnaftate tolnaftate
Indications and Usage:
Indication for effective treatment of most athleteâs foot (tinea pedis) and ringworm (tinea corporis). relieves: ⢠itching ⢠scaling ⢠cracking ⢠redness ⢠soreness ⢠burning ⢠irritation prevents the recurrence of most athleteâs foot with daily use.
Warnings:
Warnings for external use only. when using this product avoid contact with eyes.
Do Not Use:
Warnings for external use only. when using this product avoid contact with eyes.
Dosage and Administration:
Directions: for treatment of athleteâs foot, and ring worm. ⢠clean the affected area and dry thoroughly. apply a thin layer of the product over the affected area twice daily (morning and night) or as directed by a doctor. ⢠supervise children in the use of this product. ⢠for athleteâs foot: pay special attention to spaces between the toes; wear well-fitting, ventilated shoes, and change shoes and socks at least once daily. ⢠for athleteâs foot and ringworm, use daily for 4 weeks. ⢠if condition persists longer, consult a doctor. this product is not effective on the scalp or nails. to prevent athleteâs foot: ⢠wash the feet and dry thoroughly. ⢠apply a thin layer of the product to the feet once or twice daily (morningand/or night). ⢠supervise children in the use of this product. ⢠pay special attention to spaces between the toes; wear well-fitting,ventilated shoes, and change shoes and socks at least once daily
Package Label Principal Display Panel:
Product label solution
Further Questions:
Questions or comments? 1-800-826-0479 9:00 am to 5:30 pm est.